WuXi Biologics Reports Record Growth, Bets Big on Complex Drugs

HONG KONG – March 24, 2026 – WuXi Biologics has solidified its position as a powerhouse in the global biopharmaceutical services sector, announcing record-breaking financial and operational results for 2025. The company reported a 16.7% year-over-year revenue surge to RMB 21.8 billion (approx. US$3.0 billion), with net profit climbing an impressive 45.3%, underscoring a period of robust growth and strategic execution.

The performance highlights the company's successful navigation of the rapidly expanding market for biologic drugs and its critical role as a Contract Research, Development, and Manufacturing Organization (CRDMO). These organizations have become indispensable partners for pharmaceutical companies looking to outsource complex development and manufacturing, a market projected to exceed US$90 billion by the early 2030s.

A Juggernaut in a Booming Market

WuXi Biologics' financial success is not an isolated event but a reflection of its entrenchment in the burgeoning biologics industry. The company's gross profit margin expanded significantly to 46.0%, a 500-basis-point increase from the previous year, which management attributes to a favorable business mix, higher manufacturing capacity utilization, and internal efficiency programs.

These figures position WuXi Biologics strongly against key competitors like Switzerland's Lonza and South Korea's Samsung Biologics, all vying for dominance in a sector fueled by relentless innovation. The company's integrated "Follow and Win the Molecule" strategy, which aims to partner with clients from early discovery through to commercial production, has proven highly effective. This model is credited with building a massive project backlog that now stands at US$23.7 billion, providing strong visibility for future revenue. Of this, US$4.5 billion is projected to be realized within the next three years.

"In 2025, WuXi Biologics delivered record and profitable growth," said Dr. Chris Chen, CEO of WuXi Biologics, in the company's official announcement. He emphasized that the unique CRDMO model provides a "structural competitive advantage that enhances project retention and supports sustainable high growth."

Fueling Growth with Complex Biologics

A key driver of this growth is the company's strategic pivot toward more complex and higher-value biologic drugs. In 2025, WuXi Biologics signed a record 209 new integrated projects, bringing its total pipeline to 945 programs. Critically, two-thirds of these new signings were for bispecific antibodies and Antibody-Drug Conjugates (ADCs).

These next-generation therapies, which can target diseases with greater precision than traditional drugs, are at the forefront of cancer and autoimmune disease treatment. Revenue from these complex modalities grew over 120% year-over-year, now accounting for more than half of the company's entire project portfolio and nearly 20% of its total revenue.

To support this shift, the company is heavily investing in technology. It recently launched the WuXia™ TrueSite platform, a proprietary system designed to accelerate development timelines. The platform promises to take a new drug from a DNA sequence to being ready for Investigational New Drug (IND) filing in just six months, a significant acceleration in the typically lengthy drug development process.

"We are seeing accelerating momentum in complex biologics modalities, with bi- & multi-specifics and ADCs emerging as key growth drivers alongside our foundational mAb business," Dr. Chen noted, highlighting the 156 IND filings the company supported in 2025 and its expanded capacity to handle 200 INDs and 20 commercial applications annually.

Building a Resilient Global Supply Chain

Against a backdrop of shifting geopolitical landscapes and increasing focus on supply chain security, WuXi Biologics is aggressively expanding its global manufacturing footprint. This "Global Dual Sourcing" strategy aims to offer clients manufacturing options across different continents, mitigating risks and ensuring supply continuity.

In the United States, construction is progressing on a new facility in Worcester, Massachusetts, while an existing site in Cranbury, New Jersey, is being upgraded for commercial manufacturing. In Asia, a new modular drug product facility is under construction in Singapore, which is expected to be one of the largest of its kind in the world. Further extending its reach, the company signed a memorandum of understanding in December 2025 to establish a strategic hub in Qatar, marking its entry into the Middle East.

This global diversification is buttressed by an impeccable quality and compliance record. Between 2017 and 2025, the company successfully completed 46 regulatory inspections from major global authorities, including the U.S. FDA and the European Medicines Agency, with no critical findings. This track record is a crucial asset in building trust with global pharmaceutical partners who face stringent regulatory hurdles.

A Sustainable and Forward-Looking Strategy

Beyond financial performance and operational expansion, WuXi Biologics is also burnishing its credentials in Environmental, Social, and Governance (ESG). The company highlighted its inclusion in the Dow Jones Sustainability Indices and achieving a top-tier AAA ESG rating from MSCI. These accolades, along with a Platinum Medal from EcoVadis, signal a deep commitment to sustainability, a factor of growing importance for investors and partners.

The company's combination of strong financial health, a deep pipeline of next-generation drugs, a resilient global network, and a commitment to sustainability paints a picture of a company built for the future of medicine. With a workforce of over 13,000, including nearly 5,000 scientists, the organization appears well-equipped to continue its growth trajectory.

Dr. Ge Li, Chairman of WuXi Biologics, affirmed this long-term view. "Looking ahead, we remain committed to creating long-term value for our partners and strengthening our role as a trusted partner to the global biopharmaceutical industry as we advance our vision that 'every biologic can be made'."